ArticleNature2017
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.
Erratum issued 11 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph
Article in Nature, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 11 registered trials, which are not on this map. Cited by 1,071 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
1,071citing papers in PubMed, 4 pooled it
56.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Tracking Genomic Cancer Evolution in Patients for Stage IB,II and IIIA Non-small Cell Lung Cancer After Radical Resection: The Tracking Molecular Evolution for NSCLC (T-MENC) Study
Circulating Tumor DNA (ctDNA) as a Assisted Diagnosis, Early Intervention and Prognostic Marker for Peritoneal Metastases From Colorectal Cancer: A Prospective, Open-label, Randomized Controlled Study
A Randomised Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer
Safe De-escalation of Chemotherapy for Stage 1 Breast Cancer
Utility of ctDNA In Predicting Whether Giving Adjuvant Chemotherapy In Patients With Stage IB-IIA Resected Non-small Cell Lung Cancer: A Prospective Cohort Study
Gastric Cancer Detection by Liquid Biopsy in Peripheral Blood: A Prospective Study
Prediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Minimal Residual Disease Detected by Liquid Biopsy
Pancreatic Cancer Detection by Liquid Biopsy in Peripheral Blood: A Prospective Study
Pancreatic Cancer Detection by Liquid Biopsy in Peripheral Blood: A Prospective Study
Predicting NSCLC Lymph Node Metastasis: Integrating ctDNA Mutation/ Methylation Profiling With PET-CT Scan: The LUNon-invasive Study
Applications of Multiple Omics Sequencing Technologies in Predicting the Efficacy and Monitoring the Recurrence of Non-Small Cell Lung Cancer: A Prospective, Non-Interventional Study
Who cites it
1,071 citing papers in PubMed, 4 syntheses or guidelines pooled it, 1,846 citations in OpenAlex.
- Postoperative ctDNA-Guided Adjuvant Therapy in Resected Colorectal Cancer: A Systematic Review and Meta-analysis of Prognostic Validity Versus Treatment-Decision Utility.Journal of gastrointestinal cancer · 2026Pooled it
- Prognostic value of postoperative circulating tumor DNA for recurrence-free survival in resected non-small cell lung cancer: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Pooled it
- Predictive Effectiveness of Circulating Tumor DNA in Recurrent Early-Stage Non-Small Cell Lung Cancer: An Updated Meta-Analysis.JCO precision oncology · 2025Pooled it
- Late Cardiac Toxicity After Anthracyclines and Radiotherapy for Lymphoma-A Regression Analysis of Dose-Response.Hematological oncology · 2025Pooled it
- Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab.Molecular oncology · 2025Trial
- Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer: circulating tumor DNA analysis of a randomized phase 3 trial.Nature medicine · 2025Trial
- Detection of Circulating Tumor DNA Using a Tissue-Free Epigenomic Assay Is a Highly Prognostic Biomarker in Early-Stage Triple-Negative Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer.Nature medicine · 2025Trial
- Circulating MicroRNAs in non-small cell lung cancer: Clinical potential, analytic pitfalls, and barriers to implementation.The journal of liquid biopsy · 2026Review
- A multimodal AI biomarker PATH-ORACLE improves prediction of recurrence in stage I lung adenocarcinoma.Immuno-oncology technology · 2026Article
- Concordance of tumor-informed and tumor-agnostic ctDNA assays for treatment response monitoring in advanced solid tumors.The journal of liquid biopsy · 2026Article
- Value and research advances of ctDNA in perioperative therapy for non-small cell lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Micro/Nanostructured Materials and Microfluidic Diagnostic Platforms Enable Multimodal Detection of Circulating Tumor Cells.Exploration (Beijing, China) · 2026Review
- The long return on discovery science in cancer therapeutics.Nature reviews. Cancer · 2026Article
- Computational approaches for multimodal lineage tracing.Nature reviews. Genetics · 2026Review
- Multifocal ground-glass opacities in lung cancer: a narrative review of genomic evolution, immune ecology, and biology-informed clinical management.Journal of thoracic disease · 2026Review
- Perioperative Circulating Tumor DNA in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma: Molecular Residual Disease, Recurrence Prediction, and a Trial-Ready Framework for Treatment Adaptation.Journal of gastrointestinal cancer · 2026Review
- Review
- Neoantigen cancer vaccines for gastrointestinal tumors: opportunities and challenges.MedScience · 2026Review
- Dissecting residual disease in spheroids reveals pan-cancer persistence signatures and a therapeutic window for oncolytic viruses.Molecular therapy. Oncology · 2026Article
1,011 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
106 authors at 20 institutions in 6 countries.
Christopher AbboshCancer Research UK Lung Cancer Centre of Excellence London and Manchester, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6DD, UK.
Nicolai J BirkbakCancer Research UK Lung Cancer Centre of Excellence London and Manchester, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6DD, UK.
Gareth A WilsonCancer Research UK Lung Cancer Centre of Excellence London and Manchester, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6DD, UK.
Mariam Jamal-HanjaniCancer Research UK Lung Cancer Centre of Excellence London and Manchester, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6DD, UK.
Tudor ConstantinNatera Inc., 201 Industrial Road, San Carlos, California 94070, USA.
Raheleh SalariNatera Inc., 201 Industrial Road, San Carlos, California 94070, USA.
John Le QuesneCancer Studies, University of Leicester, Leicester LE2 7LX, UK.
David A MooreCancer Studies, University of Leicester, Leicester LE2 7LX, UK.
Selvaraju VeeriahCancer Research UK Lung Cancer Centre of Excellence London and Manchester, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6DD, UK.
Rachel RosenthalCancer Research UK Lung Cancer Centre of Excellence London and Manchester, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6DD, UK.
Teresa MarafiotiCancer Research UK Lung Cancer Centre of Excellence London and Manchester, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6DD, UK.
Eser KirkizlarNatera Inc., 201 Industrial Road, San Carlos, California 94070, USA.
Thomas B K WatkinsCancer Research UK Lung Cancer Centre of Excellence London and Manchester, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6DD, UK.
Nicholas McGranahanCancer Research UK Lung Cancer Centre of Excellence London and Manchester, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6DD, UK.
Sophia WardCancer Research UK Lung Cancer Centre of Excellence London and Manchester, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6DD, UK.
Luke MartinsonCancer Studies, University of Leicester, Leicester LE2 7LX, UK.
Joan RileyCancer Studies, University of Leicester, Leicester LE2 7LX, UK.
Francesco FraioliDepartment of Nuclear Medicine, University College London Hospitals, 235 Euston Road, Fitzrovia, London, NW1 2BU, UK.
Maise Al BakirTranslational Cancer Therapeutics Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
Eva GrönroosTranslational Cancer Therapeutics Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
Francisco ZambranaCancer Research UK Lung Cancer Centre of Excellence London and Manchester, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6DD, UK.
Raymondo EndozoDepartment of Nuclear Medicine, University College London Hospitals, 235 Euston Road, Fitzrovia, London, NW1 2BU, UK.
Wenya Linda BiBrigham and Women's Hospital, Boston, Massachusetts 02115, USA.
Fiona M FennessyBrigham and Women's Hospital, Boston, Massachusetts 02115, USA.
Nicole SponerNatera Inc., 201 Industrial Road, San Carlos, California 94070, USA.
Diana JohnsonCancer Research UK Lung Cancer Centre of Excellence London and Manchester, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6DD, UK.
Joanne LaycockCancer Research UK Lung Cancer Centre of Excellence London and Manchester, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6DD, UK.
Seema ShafiCancer Research UK Lung Cancer Centre of Excellence London and Manchester, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6DD, UK.
Justyna Czyzewska-KhanCancer Research UK Lung Cancer Centre of Excellence London and Manchester, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6DD, UK.
Andrew RowanTranslational Cancer Therapeutics Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
Tim ChambersTranslational Cancer Therapeutics Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
Nik MatthewsAdvanced Sequencing Facility, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
Samra TurajlicTranslational Cancer Therapeutics Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
Crispin HileyCancer Research UK Lung Cancer Centre of Excellence London and Manchester, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6DD, UK.
Siow Ming LeeCancer Research UK Lung Cancer Centre of Excellence London and Manchester, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6DD, UK.
Martin D ForsterCancer Research UK Lung Cancer Centre of Excellence London and Manchester, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6DD, UK.
Tanya AhmadDepartment of Oncology, University College London Hospitals, 250 Euston Road, London NW1 2BU, UK.
Mary FalzonDepartment of Pathology, University College London Hospitals, 21 University Street, London WC1 6JJ, UK.
Elaine BorgDepartment of Pathology, University College London Hospitals, 21 University Street, London WC1 6JJ, UK.
David LawrenceDepartment of Cardiothoracic Surgery, University College London Hospitals, 235 Euston Road, Fitzrovia, London NW1 2BU, UK.
Martin HaywardDepartment of Cardiothoracic Surgery, University College London Hospitals, 235 Euston Road, Fitzrovia, London NW1 2BU, UK.
Shyam KolvekarDepartment of Cardiothoracic Surgery, University College London Hospitals, 235 Euston Road, Fitzrovia, London NW1 2BU, UK.
Nikolaos PanagiotopoulosDepartment of Cardiothoracic Surgery, University College London Hospitals, 235 Euston Road, Fitzrovia, London NW1 2BU, UK.
Sam M JanesCancer Research UK Lung Cancer Centre of Excellence London and Manchester, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6DD, UK.
Ricky ThakrarDepartment of Respiratory Medicine, University College London Hospitals, 235 Euston Road, Fitzrovia, London NW1 2BU, UK.
Asia AhmedDepartment of Radiology, University College London Hospitals, 235 Euston Road, Fitzrovia, London NW1 2BU, UK.
Fiona BlackhallInstitute of Cancer Studies, University of Manchester, Oxford Road, Manchester M13 9PL, UK.
Yvonne SummersThe Christie Hospital, Manchester M20 4BX, UK.
Dina HafezNatera Inc., 201 Industrial Road, San Carlos, California 94070, USA.
Ashwini NaikNatera Inc., 201 Industrial Road, San Carlos, California 94070, USA.
Apratim GangulyNatera Inc., 201 Industrial Road, San Carlos, California 94070, USA.
Stephanie KarehtNatera Inc., 201 Industrial Road, San Carlos, California 94070, USA.
Rajesh ShahDepartment of Cardiothoracic Surgery, University Hospital South Manchester, Manchester M23 9LT, UK.
Leena JosephDepartment of Pathology, University Hospital South Manchester, Manchester M23 9LT, UK.
Anne Marie QuinnDepartment of Pathology, University Hospital South Manchester, Manchester M23 9LT, UK.
Phil A CrosbieNorth West Lung Centre, University Hospital South Manchester, Manchester M23 9LT, UK.
Babu NaiduDepartment of Thoracic Surgery, Birmingham Heartlands Hospital, Birmingham B9 5SS, UK.
Gary MiddletonInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, UK.
Gerald LangmanDepartment of Cellular Pathology, Birmingham Heartlands Hospital, Birmingham B9 5SS, UK.
Simon TrotterDepartment of Cellular Pathology, Birmingham Heartlands Hospital, Birmingham B9 5SS, UK.
Marianne NicolsonDepartment of Medical Oncology, Aberdeen University Medical School and Aberdeen Royal Infirmary, Aberdeen AB25 2ZN, UK.
Hardy RemmenDepartment of Cardiothoracic Surgery, Aberdeen University Medical School and Aberdeen Royal Infirmary, Aberdeen AB25 2ZD, UK.
Keith KerrDepartment of Pathology, Aberdeen University Medical School and Aberdeen Royal Infirmary, Aberdeen AB25 2ZD, UK.
Mahendran ChettyDepartment of Respiratory Medicine, Aberdeen University Medical School and Aberdeen Royal Infirmary, Aberdeen AB25 2ZN, UK.
Lesley GomersallDepartment of Radiology, Aberdeen University Medical School and Aberdeen Royal Infirmary, Aberdeen AB25 2ZN, UK.
Dean A FennellCancer Studies, University of Leicester, Leicester LE2 7LX, UK.
Apostolos NakasDepartment of Thoracic Surgery, Glenfield Hospital, Leicester LE3 9QP, UK.
Sridhar RathinamDepartment of Thoracic Surgery, Glenfield Hospital, Leicester LE3 9QP, UK.
Girija AnandDepartment of Radiotherapy, North Middlesex University Hospital, London N18 1QX, UK.
Sajid KhanDepartment of Respiratory Medicine, Royal Free Hospital, Pond Street, London NW3 2QG, UK.
Peter RussellDepartment of Respiratory Medicine, The Princess Alexandra Hospital, Hamstel Road, Harlow CM20 1QX, UK.
Veni EzhilDepartment of Clinical Oncology, St.Luke's Cancer Centre, Royal Surrey County Hospital, Guildford GU2 7XX, UK.
Babikir IsmailDepartment of Pathology, Ashford and St. Peter's Hospital, Guildford Road, Chertsey, Surrey KT16 0PZ, UK.
Melanie Irvin-SellersDepartment of Respiratory Medicine, Ashford and St. Peter's Hospital, Guildford Road, Chertsey, Surrey KT16 0PZ, UK.
Vineet PrakashDepartment of Radiology, Ashford and St. Peter's Hospital, Guildford Road, Chertsey, Surrey KT16 0PZ, UK.
Jason F LesterDepartment of Clinical Oncology, Velindre Hospital, Cardiff CF14 2TL, UK.
Malgorzata KornaszewskaDepartment of Cardiothoracic Surgery, University Hospital of Wales, Cardiff CF14 4XW, UK.
Richard AttanoosDepartment of Cellular Pathology, University Hospital of Wales and Cardiff University, Heath Park, Cardiff, UK.
Haydn AdamsDepartment of Radiology, University Hospital Llandough, Cardiff CF64 2XX, UK.
Helen DaviesDepartment of Respiratory Medicine, University Hospital Llandough, Cardiff CF64 2XX, UK.
Dahmane OukrifCancer Research UK Lung Cancer Centre of Excellence London and Manchester, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6DD, UK.
Ayse U AkarcaCancer Research UK Lung Cancer Centre of Excellence London and Manchester, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6DD, UK.
John A HartleyUniversity College London Experimental Cancer Medicine Centre GCLP Facility, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6DD, UK.
Helen L LoweUniversity College London Experimental Cancer Medicine Centre GCLP Facility, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6DD, UK.
Sara LockDepartment of Respiratory Medicine, The Whittington Hospital NHS Trust, London, N19 5NF, UK.
Natasha IlesUniversity College London, Cancer Research UK and UCL Cancer Trials Centre, London W1T 4TJ, UK.
Harriet BellUniversity College London, Cancer Research UK and UCL Cancer Trials Centre, London W1T 4TJ, UK.
Yenting NgaiUniversity College London, Cancer Research UK and UCL Cancer Trials Centre, London W1T 4TJ, UK.
Greg ElgarTranslational Cancer Therapeutics Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
Zoltan SzallasiCentre for Biological Sequence Analysis, Department of Systems Biology, Technical University of Denmark, 2800 Lyngby, Denmark.
Roland F SchwarzBerlin Institute for Medical Systems Biology, Max Delbrueck Center for Molecular Medicine, Berlin, Germany.
Javier HerreroBill Lyons Informatics Centre, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6DD, UK.
Aengus StewartDepartment of Bioinformatics and Biostatistics, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
Sergio A QuezadaCancer Immunology Unit, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6DD, UK.
Karl S PeggsCancer Immunology Unit, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6DD, UK.
Peter Van LooCancer Genomics Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
Caroline DiveCancer Research UK Lung Cancer Centre of Excellence London and Manchester, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6DD, UK.
C Jimmy LinNatera Inc., 201 Industrial Road, San Carlos, California 94070, USA.
Matthew RabinowitzNatera Inc., 201 Industrial Road, San Carlos, California 94070, USA.
Hugo J W L AertsBrigham and Women's Hospital, Boston, Massachusetts 02115, USA.
Allan HackshawUniversity College London, Cancer Research UK and UCL Cancer Trials Centre, London W1T 4TJ, UK.
Jacqui A ShawCancer Studies, University of Leicester, Leicester LE2 7LX, UK.
Bernhard G ZimmermannNatera Inc., 201 Industrial Road, San Carlos, California 94070, USA.
TRACERx consortium
PEACE consortium
Charles SwantonCancer Research UK Lung Cancer Centre of Excellence London and Manchester, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6DD, UK.
CRUK Lung Cancer Centre of Excellence · GBThe Francis Crick Institute · GBUniversity College Hospital · GBNatera (United States) · USUniversity of Leicester · GBAberdeen Royal Infirmary · GBCancer Research UK · GBBrigham and Women's Hospital · USWithington Community Hospital · GBAshford and St Peter's Hospitals NHS Foundation Trust · GBGlenfield Hospital · GBHeartlands Hospital · GBUniversity Hospital Llandough · GBUniversity Hospital of Wales · GBCancer Research UK Manchester Institute · GBInstitute of Cancer Research · GBMax Delbrück Center · DENorth Middlesex Hospital · GBPrincess Alexandra Hospital NHS Trust · GBRoyal Surrey County Hospital · GB
Funding
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MCancer Research UK 15951Cancer Research UK 15954Cancer Research UK 17786Cancer Research UK 17891Cancer Research UK 18176Cancer Research UK 18892Cancer Research UK 19278Cancer Research UK 19310Cancer Research UK 20265Cancer Research UK 20274Cancer Research UK 20275Cancer Research UK 20276Cancer Research UK 20465Cancer Research UK 20466Cancer Research UK 20613Cancer Research UK 21999Cancer Research UK 22246Cancer Research UK 22795Cancer Research UK 23896Medical Research Council G108/596Medical Research Council MC_UP_1203/1NCATS NIH HHS UL1 TR001863Wellcome Trust FC001169Wellcome Trust FC001202
Abstract
The early detection of relapse following primary surgery for non-small-cell lung cancer and the characterization of emerging subclones, which seed metastatic sites, might offer new therapeutic approaches for limiting tumour recurrence. The ability to track the evolutionary dynamics of early-stage lung cancer non-invasively in circulating tumour DNA (ctDNA) has not yet been demonstrated. Here we use a tumour-specific phylogenetic approach to profile the ctDNA of the first 100 TRACERx (Tracking Non-Small-Cell Lung Cancer Evolution Through Therapy (Rx)) study participants, including one patient who was also recruited to the PEACE (Posthumous Evaluation of Advanced Cancer Environment) post-mortem study. We identify independent predictors of ctDNA release and analyse the tumour-volume detection limit. Through blinded profiling of postoperative plasma, we observe evidence of adjuvant chemotherapy resistance and identify patients who are very likely to experience recurrence of their lung cancer. Finally, we show that phylogenetic ctDNA profiling tracks the subclonal nature of lung cancer relapse and metastasis, providing a new approach for ctDNA-driven therapeutic studies.
Indexed as
Evolution, MolecularBiopsyCarcinoma, Non-Small-Cell LungCell LineageCell TrackingClone CellsDisease ProgressionDNA Mutational AnalysisDNA, NeoplasmDrug Resistance, NeoplasmEarly Detection of CancerHumansLimit of DetectionLung NeoplasmsMultiplex Polymerase Chain ReactionNeoplasm MetastasisDNA, Neoplasm
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT03838588ClinicalTrials.gov
NCT04752930ClinicalTrials.gov
NCT04985266ClinicalTrials.gov
NCT05058183ClinicalTrials.gov
NCT05167604ClinicalTrials.gov
NCT05224596ClinicalTrials.gov
and 5 more above
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.